palmitic acid-(2-amino-ethyl ester); hydrochloride | 3936-29-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: palmitic acid-(2-amino-ethyl ester); hydrochloride
• 英文别名: Palmitinsaeure-(2-amino-aethylester); Hydrochlorid；2-Hexadecanoyloxyethylazanium;chloride；2-hexadecanoyloxyethylazanium;chloride
• CAS: 3936-29-6
• 化学式: C₁₈H₃₇NO₂*ClH
• 分子量: 335.958
• InChiKey: WJITWUUZLLQPDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.26
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-pentadecyl-4,5-dihydro-oxazole; hydrochloride 在 水 作用下， 生成 palmitic acid-(2-amino-ethyl ester); hydrochloride
  参考文献：
  名称：

  Ishii et al., Journal of Japan Oil Chemists Society, 1958, vol. 7, p. 70,71

  摘要：

  DOI：

文献信息

• Luminescent Compounds, Complexes and Their Uses
  申请人：Bligh Sim-Wan Annie

  公开号：US20140154815A1

  公开（公告）日：2014-06-05

  A method of changing the fluorescent properties of a complex, the method comprising: providing a first complex comprising a multidentate ligand that is coordinated to a lanthanide ion, wherein the lanthanide is selected from europium and terbium and the multidentate ligand has at least one optionally substituted phthalimide group coordinated to the lanthanide ion, contacting the complex with an aqueous liquid medium under appropriate conditions, such that at least one phthalimide group is hydrolysed to a phthalamate group, to form a second complex. Complexes and compounds are also disclosed.

  一种改变复合物荧光性质的方法，包括：提供第一复合物，其中包括一个多齿配体，该配体与镧系离子配位，其中镧系离子选择自铕和铽，多齿配体具有至少一个可选取代邻二酰亚胺基团与镧系离子配位；将复合物与适当条件下的水性液体接触，使至少一个邻二酰亚胺基团水解成邻二酰胺基团，形成第二复合物。还公开了复合物和化合物。
• Modified Naturally-Derived Colorants For Phase Change Ink Applications
  申请人：XEROX CORPORATION

  公开号：US20140155625A1

  公开（公告）日：2014-06-05

  A modified naturally-derived colorant comprising a naturally-derived colorant that is modified with an aliphatic quaternary ammonium salt, an aromatic quaternary ammonium salt, or a mixture or combination thereof. The modified naturally-derived colorant is compatible with phase change ink vehicles.

  一种经过改性的天然色素，包括经过改性的脂肪族季铵盐、芳香族季铵盐或两者的混合物或组合物改性的天然色素。改性的天然色素与相变墨水载体相容。
• Contrast agents
  申请人：——

  公开号：US20040146462A1

  公开（公告）日：2004-07-29

  Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration and can therefore act as deposited perfusion tracers. The preparations comprise an injectable aqueous medium comprising dispersed gas and an injectable oil-in-water emulsion in which the oil phase comprises a diffusible component capable of diffusion in vivo into the dispersed gas to promote temporary growth thereof, such that material present at the surfaces of the dispersed gas phase and material present at the surfaces of the dispersed oil phase have affinity for each other, e.g. as a result of having opposite charges. In cardiac perfusion imaging the preparations may advantageously be coadministered with vasodilator drugs such as adenosine in order to enhance the differences between return signal intensity from normal and hypoperfused myocardial tissue respectively.

  使用新型含气对比剂制剂进行超声成像，特别是心肌和其他组织的灌注成像，这些制剂促进体内气相的可控、暂时性生长，因此可以作为沉积的灌注示踪剂。这些制剂包括可注射的水性介质，其中包含分散的气体和可注射的油水乳液，其中油相包含可扩散的成分，能够在体内扩散到分散的气体中促进其暂时性生长，使分散气体相和分散油相表面的物质互相吸引，例如由于具有相反的电荷。在心脏灌注成像中，这些制剂可以优势地与血管扩张药物（如腺苷）同时使用，以增强正常和低灌注心肌组织的回波信号强度差异。
• IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS
  申请人：Marsden, John Christopher

  公开号：EP1073473A1

  公开（公告）日：2001-02-07
• [EN] IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS<br/>[FR] AMELIORATIONS APPORTEES A DES AGENTS DE CONTRASTE OU EN RAPPORT AVEC CES AGENTS
  申请人：MARSDEN, John, Christopher

  公开号：WO1999053963A1

  公开（公告）日：1999-10-28

  (EN) Ultrasonic visualisation of a subject, particularly of perfusion in the myocardium and other tissues, is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase $i(in vivo) following administration and can therefore act as deposited perfusion tracers. The preparations comprise an injectable aqueous medium comprising dispersed gas and an injectable oil-in-water emulsion in which the oil phase comprises a diffusible component capable of diffusion $i(in vivo) into the dispersed gas to promote temporary growth thereof, such that material present at the surfaces of the dispersed gas phase and material present at the surfaces of the dispersed oil phase have affinity for each other, e.g. as a result of having opposite charges. In cardiac perfusion imaging the preparations may advantageoulsy be coadministered with vasodilator drugs such as adenosine in order to enhance the differences between return signal intensity from normal and hypoperfused myocardial tissue respectively.(FR) La présente invention concerne la visualisation ultrasonique, en particulier d'une perfusion dans le myocarde et autres tissus, au moyen de nouvelles préparations d'agent de contraste renfermant du gaz. Une fois injectées, ces préparations favorisent une croissance maîtrisée et temporaire de la phase gazeuse in vivo et peuvent donc jouer le rôle de marqueurs de perfusion déposés. Les préparations renferment un milieu aqueux injectable composé de gaz à l'état de dispersion et d'une émulsion huile dans eau injectable dans laquelle la phase huileuse comprend un agent pouvant se diffuser in vivo dans le gaz dispersé et favoriser la croissance momentanée dudit gaz, de sorte que la matière présente sur les surfaces de la phase gazeuse dispersée et la matière présente sur les surfaces de la phase huileuse dispersée aient une affinité mutuelle, notamment à cause de leurs charge opposée. En ce qui concerne la visualisation de perfusions cardiaques, les préparations peuvent être utilement co-administrées avec des vasodilatateurs de type adénosine, le but étant d'accentuer les différences d'intensité entre signaux de retour selon que le tissu myocardique est normal ou en état d'hypoperfusion.